You just read:

Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 28, 2017, 11:40 ET